JP2001503396A - 治療用リポソーム組成物および方法 - Google Patents

治療用リポソーム組成物および方法

Info

Publication number
JP2001503396A
JP2001503396A JP51862298A JP51862298A JP2001503396A JP 2001503396 A JP2001503396 A JP 2001503396A JP 51862298 A JP51862298 A JP 51862298A JP 51862298 A JP51862298 A JP 51862298A JP 2001503396 A JP2001503396 A JP 2001503396A
Authority
JP
Japan
Prior art keywords
liposome
affinity moiety
hydrophilic polymer
bond
liposomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP51862298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001503396A5 (enExample
Inventor
ザリプスキー，サミュエル
ジェイ． マーティン，フランシス
クン ファン，シ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of JP2001503396A publication Critical patent/JP2001503396A/ja
Publication of JP2001503396A5 publication Critical patent/JP2001503396A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP51862298A 1996-10-11 1997-10-09 治療用リポソーム組成物および方法 Ceased JP2001503396A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2792396P 1996-10-11 1996-10-11
US60/027,923 1996-10-11
PCT/US1997/018813 WO1998016201A1 (en) 1996-10-11 1997-10-09 Therapeutic liposome composition and method

Publications (2)

Publication Number Publication Date
JP2001503396A true JP2001503396A (ja) 2001-03-13
JP2001503396A5 JP2001503396A5 (enExample) 2005-06-16

Family

ID=21840552

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51862298A Ceased JP2001503396A (ja) 1996-10-11 1997-10-09 治療用リポソーム組成物および方法

Country Status (5)

Country Link
US (3) US6043094A (enExample)
EP (1) EP0932390A1 (enExample)
JP (1) JP2001503396A (enExample)
AU (1) AU4907897A (enExample)
WO (1) WO1998016201A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002542341A (ja) * 1999-04-20 2002-12-10 ザ ユニバーシティ オブ ブリティッシュ コロンビア カチオン性ｐｅｇ脂質および使用方法。
JP2005513104A (ja) * 2001-12-06 2005-05-12 イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム テンパミン（ｔｅｍｐａｍｉｎｅ）組成物および使用方法
JPWO2008026781A1 (ja) * 2006-08-31 2010-01-21 直人 奥 逆標的化脂質小胞体
JP2010150264A (ja) * 2005-12-19 2010-07-08 Ind Technol Res Inst グルタチオンベースデリバリーシステム
JP2013515767A (ja) * 2009-12-29 2013-05-09 キョンブク ナショナル ユニバーシティ インダストリー−アカデミック コーオペレーション ファウンデーション インターロイキン−４受容体を特異的に標的とするペプチドで標識されたリポソームを含有する癌診断又は治療用標的指向型薬物伝達システム、及びその製造方法
US8673863B2 (en) 2005-12-19 2014-03-18 Industrial Technology Research Institute Glutathione-based delivery system
JP2020026397A (ja) * 2018-08-09 2020-02-20 国立大学法人 岡山大学 ＴｒｋＢアンタゴニストを含む医薬組成物

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780222A (en) 1995-04-10 1998-07-14 Alpha Therapeutic Corporation Method of PCR testing of pooled blood samples
WO1998016201A1 (en) * 1996-10-11 1998-04-23 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US20020115609A1 (en) * 1997-07-14 2002-08-22 Hayat Onyuksel Materials and methods for making improved micelle compositions
US20050025819A1 (en) * 1997-07-14 2005-02-03 Hayat Onyuksel Materials and methods for making improved micelle compositions
US6372720B1 (en) 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
BR9912053A (pt) * 1998-07-13 2001-04-03 Univ Texas Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios
EP1096955B9 (en) 1998-07-13 2006-07-05 Board of Regents, The University of Texas System Uses of antibodies to aminophospholipids for cancer treatment
US6379698B1 (en) * 1999-04-06 2002-04-30 Isis Pharmaceuticals, Inc. Fusogenic lipids and vesicles
HUP0201425A3 (en) 1999-04-23 2006-07-28 Hadasit Med Res Service Conjugate having a cleavable linkage for use in a liposome
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US7390780B2 (en) * 1999-04-23 2008-06-24 Alza Corporation Gene delivery mediated by liposome-DNA complex with cleavable peg surface modification
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
AUPQ014699A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
WO2001041738A2 (en) * 1999-12-10 2001-06-14 Celator Technologies Inc. Lipid carrier compositions with protected surface reactive functions
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
AU2002225878A1 (en) * 2000-11-02 2002-05-15 Smith Kline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
CA2435287A1 (en) * 2001-01-17 2002-07-25 Zycos Inc. Nucleic acid delivery formulations
HUP0303616A3 (en) * 2001-03-26 2006-07-28 Alza Corp Mountain View Liposome composition for improved intracellular delivery of a therapeutic agent
WO2002078672A2 (en) * 2001-03-30 2002-10-10 Alza Corporation Liposomal tumor necrosis factor compositions and methods
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
JP2005527639A (ja) 2001-11-02 2005-09-15 インサート セラピューティクス インコーポレイテッド Ｒｎａ干渉の治療的利用のための方法及び組成物
US20040147466A1 (en) * 2002-01-17 2004-07-29 Barman Shikha P. Nucleic acid delivery formulations
DE10207178A1 (de) * 2002-02-19 2003-09-04 Novosom Ag Komponenten für die Herstellung amphoterer Liposomen
US7211250B2 (en) 2002-07-18 2007-05-01 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
US20040161468A1 (en) * 2002-12-04 2004-08-19 L'oreal Stabilization of aromatic active principles using aromatic polymers
FR2848101B1 (fr) * 2002-12-04 2006-08-11 Oreal Procede de traitement cosmetique des matieres keratiniques impliquant la liberation controlee de principes actifs aromatiques a partir de particules de polymere aromatique
CA2510780A1 (en) * 2002-12-19 2004-07-08 Alza Corporation Method of treating angiogenic tissue growth
ATE512674T1 (de) 2003-01-06 2011-07-15 Angiochem Inc Angiopep-1, verwandte verbindungen, und deren verwnedungen
WO2004087097A2 (en) * 2003-03-31 2004-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
US20060115523A1 (en) * 2004-12-01 2006-06-01 Konduri Kameswari S Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal
US11324698B2 (en) 2003-08-28 2022-05-10 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US8846079B1 (en) 2004-12-01 2014-09-30 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
IL158599A0 (en) * 2003-10-26 2004-05-12 Yeda Res & Dev Methods of modulating hematopoiesis
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
EP1737487B1 (en) * 2004-03-30 2016-05-25 Canadian Blood Services Method for treating autoimmune diseases with antibodies
ZA200609638B (en) * 2004-04-21 2008-02-27 Alza Corp Polymer conjugate releasable under mild thiolytic conditions
US20050281798A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting sites of damaged lung tissue using composition
US7553810B2 (en) * 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US20050281799A1 (en) 2004-06-16 2005-12-22 Glen Gong Targeting damaged lung tissue using compositions
US20050281739A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue using compositions
US7608579B2 (en) * 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
CA2570261C (en) * 2004-07-08 2014-06-10 Pneumrx, Inc. Pleural effusion treatment device, method and material
AU2005281352B2 (en) * 2004-09-09 2011-01-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal compositions of glucocorticoid and glucocorticoid derivatives
US20080063702A1 (en) * 2004-09-09 2008-03-13 Yechezkel Barenholz Liposomal Formulations Comprising an Amphipathic Weak Base Like Tempamine for Treatment of Neurodegenerative Conditions
US6998028B1 (en) * 2004-09-24 2006-02-14 Superpower, Inc. Methods for forming superconducting conductors
TW200612993A (en) * 2004-10-08 2006-05-01 Alza Corp Lipopolymer conjugates
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
AU2005303389A1 (en) * 2004-11-15 2006-05-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combination therapy associating preferably a ceramide with a cytotoxic drug
MX2007010113A (es) * 2005-02-18 2007-12-07 Angiochem Inc Polipeptidos de aprotinina para transportar un compuesto a traves de la barrera hematoencefalica.
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
WO2007005754A2 (en) * 2005-07-01 2007-01-11 Alza Corporation Liposomal delivery vehicle for hydrophobic drugs
PL2233156T3 (pl) 2005-07-15 2013-09-30 Angiochem Inc Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych
US8591457B2 (en) * 2005-08-10 2013-11-26 Alza Corporation Method for making a needle-free jet injection drug delivery device
WO2007038246A2 (en) 2005-09-22 2007-04-05 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
CA2623198C (en) 2005-09-22 2014-08-05 Medivas, Llc Bis-(a-amino)-diol-diester-containing poly(ester amide) and poly(ester urethane) compositions and methods of use
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
AU2006294644A1 (en) * 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
CN101365424A (zh) * 2005-12-08 2009-02-11 耶路撒冷希伯来大学伊森姆研究发展公司 通过超声辐射改变脂质体组成的方法
CA2841386A1 (en) 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
US8597636B2 (en) * 2006-01-13 2013-12-03 Canadian Blood Services Method for treating autoimmune diseases and compositions therefor
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
DE102007004303A1 (de) * 2006-08-04 2008-02-07 Osram Opto Semiconductors Gmbh Dünnfilm-Halbleiterbauelement und Bauelement-Verbund
US20090054317A1 (en) * 2006-08-14 2009-02-26 Kane Ravindra S Polyvalent inhibitors of pathogens
US20100297218A1 (en) * 2006-09-20 2010-11-25 Pneumrx, Inc. Tissue adhesive compositions and methods thereof
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
WO2009006311A2 (en) * 2007-06-29 2009-01-08 Wisconsin Alumni Research Foundation Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
CA2695374A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
TW200918099A (en) * 2007-09-14 2009-05-01 Nitto Denko Corp Drug carriers
JP2011520769A (ja) * 2007-09-21 2011-07-21 サイトイミューン サイエンシズ インコーポレイテッド ナノ治療コロイド金属組成物および方法
WO2009076323A2 (en) 2007-12-06 2009-06-18 Genalyte Inc. Monitoring enzymatic process
CN102026667B (zh) * 2008-04-18 2014-06-25 安吉奥开米公司 紫杉醇、紫杉醇类似物或紫杉醇结合物的药物组合物及相关制备方法和用途
US8231895B2 (en) 2008-05-22 2012-07-31 Universidade De Coimbra Targeted delivery to human diseases and disorders
US8239357B1 (en) * 2008-09-12 2012-08-07 Ryan, LLC Method and system for extracting information from electronic data sources
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
US8828925B2 (en) 2008-10-15 2014-09-09 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
EP2347247B1 (en) 2008-10-27 2019-06-26 Genalyte, Inc. Biosensors based on optical probing and sensing
WO2010063122A1 (en) * 2008-12-05 2010-06-10 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
EP2373789A4 (en) 2008-12-17 2012-08-29 Angiochem Inc MEMBRANTYP-1 MATRIX METALLOPROTEINASE INHIBITORS AND THEIR USE
AU2009337181A1 (en) * 2009-01-15 2011-08-04 Board Of Regents Of The University Of Texas System Porous structures with modified biodegradation kinetics
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
DE102009012640A1 (de) * 2009-03-09 2010-09-30 Freie Universität Berlin Mit einer Phosphoamidatgruppe modifizierte Verbindung und deren Verwendung
RU2011146654A (ru) 2009-04-20 2013-05-27 Ангиокем Инк. Способы лечения рака яичников с применением конъюгированного средства
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
PE20121539A1 (es) 2009-06-08 2012-12-06 Amunix Operating Inc Polipeptidos de la hormona de crecimiento y metodos de preparacion
WO2010143193A1 (en) 2009-06-11 2010-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Targeted liposomes comprising n-containing bisphosphonates and uses thereof
WO2011000095A1 (en) 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
BR112012009801A8 (pt) 2009-10-30 2016-08-30 Cns Therapeutics Inc Polipeptídeo neurturina e variante de neurturina
WO2011092708A2 (en) 2010-02-01 2011-08-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation
EP2635710B1 (en) 2010-11-05 2017-08-09 Genalyte, Inc. Optical analyte detection systems and methods of use
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
ES2558357T3 (es) 2011-06-23 2016-02-03 Dsm Ip Assets B.V. Micro- o nanopartículas que comprenden un copolímero de poliesteramida biodegradable para uso en el suministro de agentes bioactivos
LT2731591T (lt) 2011-07-13 2020-12-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Liposomos, kuriose kartu inkapsuliuotas bisfosfonatas ir amfipatinis agentas
WO2013114377A1 (en) 2012-02-02 2013-08-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd Stable liposomes for drug delivery
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
US20130261010A1 (en) 2012-03-12 2013-10-03 The Board Of Trustees Of The University Of Illinois Optical analyte detection systems with magnetic enhancement and methods of use
US9156897B2 (en) 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
CN102920658B (zh) * 2012-11-02 2015-01-21 艾韦特(溧阳)医药科技有限公司 与glp-1类似物和聚乙二醇结合的脂质体及其制备方法
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
BR112016011195A2 (pt) 2013-11-18 2017-09-19 Rubius Therapeutics Inc Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
CN107124869B (zh) 2014-03-25 2022-04-01 美国政府陆军部 包含含有单磷酰脂质a（mpla）的脂质体组合物和皂苷的无毒佐剂制剂
US20170173005A1 (en) 2014-03-27 2017-06-22 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
CN106456744A (zh) 2014-04-01 2017-02-22 鲁比厄斯治疗法股份有限公司 用于免疫调节的方法和组合物
CA2969171C (en) 2014-12-18 2023-12-12 Dsm Ip Assets B.V. Drug delivery system for delivery of acid sensitive drugs
EP3261678B8 (en) 2015-01-23 2021-03-17 Helix Biopharma Corp. Antibody-urease conjugates for therapeutic purposes
AU2016233143B2 (en) 2015-03-17 2021-03-25 Alberto Gabizon Methods for the treatment of bladder cancer
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
CN108289845A (zh) 2015-09-14 2018-07-17 维吉思康科技公司 皮下、舌下和口服治疗用空间稳定载体、用于治疗哺乳动物的组合物和方法
IL286493B (en) 2015-11-06 2022-07-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogues, methods of producing same, compositions comprising same and uses thereof
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
US11260132B2 (en) 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
CN110582282A (zh) 2017-04-25 2019-12-17 佐剂技术公司 三萜皂苷类似物
JP2020536946A (ja) 2017-10-16 2020-12-17 アジュバンス・テクノロジーズ・インコーポレーテッド トリテルペンサポニン類似物
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
AU2020379738A1 (en) 2019-11-05 2022-04-14 Adjuvance Technologies, Inc. Varicella zoster
EP4058504A1 (en) 2019-11-12 2022-09-21 DSM IP Assets B.V. Polyesteramide copolymers possessing high glass transition temperatures
PH12022553407A1 (en) 2020-06-25 2024-04-22 Amunix Pharmaceuticals Inc Her-2 targeted bispecific compositions and methods for making and using the same
WO2022204267A1 (en) 2021-03-24 2022-09-29 Alkermes, Inc. Upar antibodies and fusion proteins with the same
AU2022270670A1 (en) 2021-05-05 2023-11-30 Nejat Duzgunes Liposome-encapsulated corticosteriods inhibit sars-cov-2 replication and reduces lung inflammation
AU2023235562B2 (en) 2022-03-14 2026-07-30 Pfizer Inc. Methods for producing an adjuvant
CN120513083A (zh) 2022-12-01 2025-08-19 辉瑞大药厂 肺炎链球菌缀合物疫苗制剂
TWI909678B (zh) 2023-09-13 2025-12-21 美商輝瑞股份有限公司 產製佐劑之方法
TW202602467A (zh) 2024-03-11 2026-01-16 美商輝瑞股份有限公司 包含經共軛之大腸桿菌糖的免疫原性組成物及其用途
WO2026088120A1 (en) 2024-10-24 2026-04-30 Pfizer Inc. Lipidated tlr7/8 modulators as adjuvants and uses thereof
US20260166136A1 (en) 2024-12-18 2026-06-18 Pfizer Inc. Immunogenic compositions and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4952394A (en) * 1987-11-23 1990-08-28 Bristol-Myers Company Drug-monoclonal antibody conjugates
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
AU6368394A (en) * 1993-03-23 1994-10-11 Liposome Technology, Inc. Polymer-polypeptide composition and method
WO1998016201A1 (en) * 1996-10-11 1998-04-23 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002542341A (ja) * 1999-04-20 2002-12-10 ザ ユニバーシティ オブ ブリティッシュ コロンビア カチオン性ｐｅｇ脂質および使用方法。
JP2005513104A (ja) * 2001-12-06 2005-05-12 イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム テンパミン（ｔｅｍｐａｍｉｎｅ）組成物および使用方法
JP2010150264A (ja) * 2005-12-19 2010-07-08 Ind Technol Res Inst グルタチオンベースデリバリーシステム
US8673863B2 (en) 2005-12-19 2014-03-18 Industrial Technology Research Institute Glutathione-based delivery system
JPWO2008026781A1 (ja) * 2006-08-31 2010-01-21 直人 奥 逆標的化脂質小胞体
JP2013515767A (ja) * 2009-12-29 2013-05-09 キョンブク ナショナル ユニバーシティ インダストリー−アカデミック コーオペレーション ファウンデーション インターロイキン−４受容体を特異的に標的とするペプチドで標識されたリポソームを含有する癌診断又は治療用標的指向型薬物伝達システム、及びその製造方法
JP2020026397A (ja) * 2018-08-09 2020-02-20 国立大学法人 岡山大学 ＴｒｋＢアンタゴニストを含む医薬組成物

Also Published As

Publication number Publication date
WO1998016201A1 (en) 1998-04-23
AU4907897A (en) 1998-05-11
EP0932390A1 (en) 1999-08-04
US20020102733A1 (en) 2002-08-01
US6660525B2 (en) 2003-12-09
US20040009217A1 (en) 2004-01-15
US6958241B2 (en) 2005-10-25
US6043094A (en) 2000-03-28

Similar Documents

Publication Publication Date Title
US6958241B2 (en) Therapeutic liposome composition and method
CA2157410C (en) Enhanced circulation effector composition and method
US6224903B1 (en) Polymer-lipid conjugate for fusion of target membranes
US7060291B1 (en) Modular targeted liposomal delivery system
US6027726A (en) Glycosylated protein-liposome conjugates and methods for their preparation
AU715063B2 (en) Fusogenic liposome composition and method
US6180134B1 (en) Enhanced ciruclation effector composition and method
US6936272B2 (en) 10139483Therapeutic liposome composition and method of preparation
US20020192275A1 (en) Liposome composition for improved intracellular delivery of a therapeutic agent
KR20240141854A (ko) 알파 및 감마-d 폴리글루타메이트화 항엽산 및 이의 용도
US5366958A (en) Localized delivery using fibronectin conjugates
AU2002305094A1 (en) Liposome composition for improved intracellular delivery of a therapeutic agent
JP3671054B2 (ja) 医薬組成物
JP2003530362A (ja) 診断剤をターゲッティングするための脂質ベースの系
KR100355247B1 (ko) 다층라멜라리포좀성아라키돈산대사물질
EP1231895B1 (en) Modular targeted liposomal delivery system
JP2006519262A (ja) リポソームにより誘導される補体活性化の減少のためのリポソーム組成物
JPWO2005021012A1 (ja) ゲムシタビン封入薬剤担体
US5419914A (en) Phospholipid analogue vesicle
WO1997031624A1 (en) Liposomal delivery system
Kumar et al. Liposome–a novel colloidal drug delivery system
Sanderson Interaction of cationic liposomes with the skin-associated bacteria Staphylococcus epidermis for the delivery of antibacterial agents
MXPA99003336A (en) Fusogenic liposome composition and method

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041008

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041008

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20061227

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20061227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080610

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20081104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090106